Company profile for Walden Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. We utilize ou...
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. We utilize our mechanistic understanding of kidney function in health and disease to provide patients with real treatment options, which target the kidney at the site of drug action.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
One Kendall Square, Suite 7102 Cambridge, MA 02139
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/04/3144313/0/en/Walden-Biosciences-Announces-Key-Initiatives-to-Advance-Clinical-Pipeline-and-Support-Phase-2-Program-for-WAL0921-in-Rare-Kidney-Diseases.html

GLOBENEWSWIRE
04 Sep 2025

https://www.globenewswire.com/news-release/2025/01/28/3016245/0/en/Walden-Biosciences-Appoints-Howard-Mayer-M-D-to-Board-of-Directors.html

GLOBENEWSWIRE
28 Jan 2025

https://www.globenewswire.com/news-release/2025/01/10/3007547/0/en/Walden-Biosciences-Highlights-2024-Accomplishments-and-2025-Priorities.html

GLOBENEWSWIRE
10 Jan 2025

https://www.globenewswire.com/en/news-release/2024/09/30/2955059/0/en/Walden-Biosciences-Fully-Enrolls-First-Cohort-in-Phase-2-Basket-Study-of-WAL0921-in-Chronic-Kidney-Diseases.html

GLOBENEWSWIRE
30 Sep 2024
Walden Biosciences teams up with Primula for kidney disease study
Walden Biosciences teams up with Primula for kidney disease study

14 May 2024

// Jenna Philpott PHARMACEUTICAL TECHNOLOGY

https://www.pharmaceutical-technology.com/news/walden-biosciences-teams-up-with-primula-for-kidney-disease-study/

Jenna Philpott PHARMACEUTICAL TECHNOLOGY
14 May 2024

https://www.globenewswire.com/news-release/2024/05/13/2880269/0/en/Walden-Biosciences-Announces-Research-Collaboration-with-World-Renowned-Genetic-Epidemiologist-to-Advance-Work-on-Causal-Role-of-suPAR-in-Chronic-Kidney-Disease.html

GLOBENEWSWIRE
13 May 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty